| | October 20188CIOReview | | August 20188CIOReviewlobal Capability Centres (GCCs) is now an established phenomenon for most of the major Global Pharma players. These centres have resulted in considerable cost savings and an improved customer service to business and end users. With IT budget flat-tening, companies are increasingly looking at the GCCs to move up the value chain and go beyond the tradition-al Application Maintenance and Development services.Breaking the myth and thought barriers on the kind of services which can and cannot be delivered from off-shore centres is now becoming the next big focus area for GCC leaders. And the opportunities are enormous1. Technology COEs - Pharma, which was histori-cally perceived as a tech conservative sector, is fast com-ing to the forefront of adopting cutting-edge technolo-gies including AI, Analytics, Robotics, IOT. GCCs can play a critical role to incubate the technologies and build a talent pool who will engineer future transformation programs on these technologies.2. New Roles - Roles like Solution Architects and Business Analysts, which were earlier perceived to be done only by sitting in customer proximity have started trickling down to the GCCs. This is aided by the fact that since most of the technical teams and expertise are present in the GCCs, work like Solution Blueprinting, Process Reengineering can be worked upon by architects and analysts co-located with the technical engineers. With technologies like RPA being incubated new roles like Process Mentor, Automation Orchestrator are also getting added to the GCCs.3. Data Science - With the number of Biotech gradu-ates on the rise from both Tier 1 colleges like the IITs as well as Tier 2 colleges, candidates with a mix of Bi-ology and Computer Science backgrounds are easier to recruit. These candidates can prove useful in offshoring of Data Science work especially in areas like Genomics and Cheminformatics.4. Commercial Innovation - India has historically not been an attractive market for pharma companies due to GIN MY OPINIONPHARMA CAPTIVE CENTRES - MOVING UP THE VALUE CHAIN By Furhan Ahmed, Director IT, Science and Enabling Units at AstraZeneca
< Page 7 | Page 9 >